State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI

Eric A. Engels, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Meredith S. Shiels, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Ruanne V. Barnabas, Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Julia Bohlius, University of Basel, Basel, Switzerland.
Paul Brennan, Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Jessica Castilho, Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Stephen J. Chanock, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Megan A. Clarke, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Anna E. Coghill, Department of Cancer Epidemiology and Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Jean-Damien Combes, International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.
Scott Dryden-Peterson, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Gypsyamber D'Souza, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Satish Gopal, Center for Global Health, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Antoine Jaquet, National Institute for Health and Medical Research (INSERM), UMR, 1219, Research Institute for Sustainable Development (IRD), EMR 271, Bordeaux Population, Health Centre, University of Bordeaux, Bordeaux, France.
Kathryn Lurain, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Alain Makinson, Infectious Disease Department, CHU La Colombière, Montpellier & Inserm U1175, University of Montpellier, Montpellier, France.
Jeffrey Martin, Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Mazvita Muchengeti, National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa.
Robert Newton, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
Fred Okuku, Uganda Cancer Institute, Kampala, Uganda.
Jackson Orem, Uganda Cancer Institute, Kampala, Uganda.
Joel M. Palefsky, Department of Medicine, University of California, San Francisco, California, USA.
Ramya Ramaswami, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Hilary A. Robbins, Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Keith Sigel, Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sylvia Silver, George Washington University, Washington, DC, USA.
Gita Suneja, Department of Radiation Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, USA.
Robert Yarchoan, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gary M. Clifford, International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.

Document Type

Journal Article

Publication Date

9-15-2023

Journal

International journal of cancer

DOI

10.1002/ijc.34727

Keywords

cancer; epidemiology; human immunodeficiency virus; people living with HIV; prevention

Abstract

An estimated 38 million people live with human immunodeficiency virus (HIV) worldwide and are at excess risk for multiple cancer types. Elevated cancer risks in people living with HIV (PLWH) are driven primarily by increased exposure to carcinogens, most notably oncogenic viruses acquired through shared transmission routes, plus acceleration of viral carcinogenesis by HIV-related immunosuppression. In the era of widespread antiretroviral therapy (ART), life expectancy of PLWH has increased, with cancer now a leading cause of co-morbidity and death. Furthermore, the types of cancers occurring among PLWH are shifting over time and vary in their relative burden in different parts of the world. In this context, the International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) convened a meeting in September 2022 of multinational and multidisciplinary experts to focus on cancer in PLWH. This report summarizes the proceedings, including a review of the state of the science of cancer descriptive epidemiology, etiology, molecular tumor characterization, primary and secondary prevention, treatment disparities and survival in PLWH around the world. A consensus of key research priorities and recommendations in these domains is also presented.

Department

Microbiology, Immunology, and Tropical Medicine

Link to Full Text

Share

COinS